Combination therapy for erectile dysfunction involving a pde5 inhibitor and alprostadil

ABSTRACT The phosphodiesterase-5 inhibitors (PDE5Is) are the first-line treatment option for men with erectile dysfunction (ED), with alprostadil considered a second-line choice.

Consideration has to be given to patients who fail these treatments and what their options are. This review evaluates the data on the combination of a PDE5I with alprostadil in patients who

have previously failed therapy with either drug. A PubMed search was conducted and identified nine publications relating to combination treatment with alprostadil as intracavernosal,

intraurethral or topical application. The results indicate that with all three formulations the combination therapy resulted in an improved outcome compared with either of the drugs as

monotherapy. This was demonstrated by the increased total International Index of Erectile Function (IIEF) scores as well as IIEF erectile function domain scores. This finding was also valid

for patients with post-prostatectomy ED. The associated side effects of the combined treatment did not result in treatment discontinuation. These findings suggest that combination therapy

with a PDE5I and alprostadil might be considered a treatment option in patients who have previously had a poor response to either drug. Access through your institution Buy or subscribe This

is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00

per year only $21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS COMBINATION

THERAPY WITH TOPICAL ALPROSTADIL AND PHOSPHODIESTERASE-5 INHIBITORS AFTER FAILURE OF ORAL THERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION: A PROSPECTIVE, TWO-ARM, OPEN-LABEL, NON-RANDOMIZED

STUDY Article 22 January 2021 MIRABEGRON IMPROVES ERECTILE FUNCTION IN MEN WITH OVERACTIVE BLADDER AND ERECTILE DYSFUNCTION: A 12-WEEK PILOT STUDY Article 02 July 2021 CURRENT MANAGEMENT

STRATEGY OF TREATING PATIENTS WITH ERECTILE DYSFUNCTION AFTER RADICAL PROSTATECTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS Article 24 October 2020 REFERENCES * McCabe MP, Sharlip ID, Lewis

R, Atalla E, Balon R, Fisher AD, et al. Incidence and prevalence of sexual dysfunction in women and men: A consensus statement from the fourth international consultation on sexual medicine

2015. J Sex Med. 2016;13:144–52. Article  Google Scholar  * Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P et al. European Association of Urology Guidelines on Male

Sexual Dysfunction https://uroweb.org/guideline/male-sexual-dysfunction. Accessed November 2017, 18–21 * Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–13. Article  CAS  PubMed 

Google Scholar  * Hanchanale V, Eadley I. Alprostadil for the treatment of impotence. Expert Opin Pharmacother. 2014;15:421–8. Article  CAS  PubMed  Google Scholar  * McMahon C, Samali R,

Johnson H. Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999;162:1992–8. Article  CAS

  PubMed  Google Scholar  * Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual

activity and the return of natural erections. Int J Impot Res. 2006;18:446–51. Article  CAS  PubMed  Google Scholar  * Gutierrez P, Hernandez P, Mas M. Combining programmed intracavernous

PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders. Int J Impot Res. 2005;17:354–8. Article  CAS  Google Scholar  * Mydlo JH, Viterbo R, Crispen P. Use of combined

intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU

Int. 2005;95:843–6. Article  CAS  PubMed  Google Scholar  * Mydlo JH, Volpe MA, Macchia RJ. Initial results utilizing combination therapy for patients with a suboptimal response to either

alprostadil or sildenafil monotherapy. Eur Urol. 2000;38:30–4. Article  CAS  Google Scholar  * Raina R, Nandipati KC, Agarwal A, Mansour D, Kaelber DC, Zippe CD, et al. Combination therapy:

medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. J Androl. 2005;26:757–60. Article  CAS 

PubMed  Google Scholar  * Labairu-Huerta L, Padilla-Fernández B, Arrondo-Arrondo JL, Valverde-Martínez LS, Martín-Rodríguez A, Silva-Abuín JM, et al. PDE-5 inhibitors in monotherapy versus

combination therapy in a sample of 1200 patients with erectile dysfunction. Arch Ital Urol Androl. 2015;87:204–9. Article  CAS  PubMed  Google Scholar  * Nehra A, Blute ML, Barrett DM,

Moreland RB. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. Int J Impot

Res. 2002;14(Suppl 1):S38–42. Article  PubMed  Google Scholar  * Goldstein I, Mulhall JP, Bushmakin AG, Cappelleri JC, Hvidsten K, Symonds T. The erection hardness score and its relationship

to successful sexual intercourse. J Sex Med. 2008;5:2374–80. Article  PubMed  Google Scholar  * Huang ST, Jiann BP. Assessing satisfaction in men and their female partners after treatment

with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Impot Res. 2013;25:178–82. Article  CAS  PubMed  Google Scholar  * Virag R. Intracavernous injection of papaverine

for erectile failure. Lancet 1982;2:938. Article  CAS  PubMed  Google Scholar  * Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile

dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336:1–7. Article  CAS  PubMed  Google Scholar  * Moncada I, Cuzin

B. Clinical efficacy and safety of Vitaros©/Virirec© (Alprstadil cream) for the treatment of erectile dysfunction. Urologia. 2015;82:84–92. Article  PubMed  Google Scholar  * Wolka AM,

Rytting JH, Reed BL, Finnin BC. The interaction of the penetration enhancer DDAIP with a phospholipid model membrane. Int J Pharm. 2004;271:5–10. Article  CAS  PubMed  Google Scholar  *

Padma-Nathan H, Steidle C, Salem S, Tayse N, Yeager J, Harning R. The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2

studies in mild-to-moderate and severe ED. Int J Impot Res. 2003;15:10–7. Article  CAS  PubMed  Google Scholar  * Steers WD. Viability and safety of combination drug therapies for erectile

dysfunction. J Urol. 2003;170(2 Pt 2):S20–23. Article  PubMed  Google Scholar  * McMahon CG. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous

injection therapy. Int J Impot Res. 2003;15:383–4. Article  CAS  PubMed  Google Scholar  * Chew K-K, Stuckey BGA, Earle CM, Dhaliwal, Keogh EJ. Penile fibrosis in intracavernosal

prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res. 1997;9:225–9. Article  CAS  PubMed  Google Scholar  * Barthelmes L, Chezhian C, Aihaku EK. Deep venous

thrombosis and venous thrombophlebitis associated with alprostadil treatment for erectile dysfunction. Int J Impot Res. 2002;14:199–200. Article  CAS  PubMed  Google Scholar  * Yeager J,

Beihn RM. Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction. Int J Impot Res. 2005;17:91–5. Article  CAS  PubMed  Google Scholar 

Download references ACKNOWLEDGEMENTS Editorial support provided by Medscimedia Ltd and funded by Casen Recordati. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Urology Department, Hospital

La Zarzuela c/Pléyades, Madrid, Spain I. Moncada * Urology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain J. Martinez-Salamanca * Urology Department, Fundació

Puigvert, Barcelona, Spain E. Ruiz-Castañe * Urology Department, Hospital Universitario 12 de Octubre, Madrid, Spain J. Romero Authors * I. Moncada View author publications You can also

search for this author inPubMed Google Scholar * J. Martinez-Salamanca View author publications You can also search for this author inPubMed Google Scholar * E. Ruiz-Castañe View author

publications You can also search for this author inPubMed Google Scholar * J. Romero View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR

Correspondence to I. Moncada. ETHICS DECLARATIONS CONFLICT OF INTEREST IM has taken part in Advisory Board meetings and also acted as a speaker for Casen Recordati and Ferring. The

remaining authors declare that they have no conflict of interest. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Moncada, I., Martinez-Salamanca, J.,

Ruiz-Castañe, E. _et al._ Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. _Int J Impot Res_ 30, 203–208 (2018).

https://doi.org/10.1038/s41443-018-0046-2 Download citation * Received: 25 January 2018 * Revised: 10 May 2018 * Accepted: 20 May 2018 * Published: 26 July 2018 * Issue Date: October 2018 *

DOI: https://doi.org/10.1038/s41443-018-0046-2 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is

not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative